Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lengthening Adalimumab Dosing Interval in quiescent Crohn's disease patients (LADI)
2016-003321-42Phase 4Active
- Sponsor
- Radboud University Medical Center
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of adalimumab in Crohn's disease (2 arms), sponsored by Radboud University Medical Center. Started Dec 2016; status: active.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2016-003321-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003321-42.